A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.

Trial Details

NCT ID
NCT06533332
Phase
PHASE1
Sponsor
EtiraRx Australia Pty Ltd
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ERX-315
Locations (sample)
  • Ryde, New South Wales, Australia|-33.8188,151.1062
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Westmead, New South Wales, Australia|-33.80383,150.98768
  • Adelaide, South Australia, Australia|-34.92866,138.59863
  • Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Patients must be at least 18 years of age at the time of signing the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endom…
  • Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →